# Leisha A Emens

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 103 papers | 8,502 citations | 39 h-index | 92 g-index |
| 115 ext. papers | 11,309 ext. citations | 6.7 avg, IF | 6.69 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 103 | A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.. *Surgical Pathology Clinics*, **2022**, 15, 105-120 | 3.9 | 0 |
| 102 | Abstract OT1-12-02: Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab. *Cancer Research*, **2022**, 82, OT1-12-02-OT1-12-02 | 10.1 | |
| 101 | Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC). *Cancer Research*, **2022**, 82, GS2-10-GS2-10 | 10.1 | 0 |
| 100 | Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies. *Breast Cancer Research and Treatment*, **2021**, 1 | 4.4 | 3 |
| 99 | Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy. *Journal of the National Cancer Institute*, **2021**, | 9.7 | 1 |
| 98 | Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. *JAMA Network Open*, **2021**, 4, e216322 | 10.4 | 2 |
| 97 | Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.. *Journal of Clinical Oncology*, **2021**, 39, TPS1111-TPS1111 | 2.2 | |
| 96 | Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. *Clinical Breast Cancer*, **2021**, 21, 539-551 | 3 | 4 |
| 95 | PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. *Journal of the National Cancer Institute*, **2021**, | 9.7 | 21 |
| 94 | Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice. *Current Oncology*, **2021**, 28, 2741-2752 | 2.8 | |
| 93 | Immunotherapy in Triple-Negative Breast Cancer. *Cancer Journal (Sudbury, Mass.)*, **2021**, 27, 59-66 | 2.2 | 10 |
| 92 | Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. *Journal of the National Cancer Institute*, **2021**, 113, 1005-1016 | 9.7 | 56 |
| 91 | Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer **2021**, 9, | | 4 |
| 90 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer **2021**, 9, | | 7 |
| 89 | First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. *Annals of Oncology*, **2021**, 32, 983-993 | 10.3 | 35 |
| 88 | The evolving management of metastatic triple negative breast cancer. *Seminars in Oncology*, **2020**, 47, 229-237 | 5.5 | 12 |
| 87 | Cytokine profiling of tumor-infiltrating T lymphocytes by flow cytometry. *Methods in Enzymology*, **2020**, 631, 1-20 | 1.7 | |

| | | | |
|---|---|---|---|
| 86 | 317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors **2020**, 8, A343-A343 | | 1 |
| 85 | Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. *Cancer Treatment Reviews*, **2020**, 84, 101947 | 14.4 | 21 |
| 84 | Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. *Cancer Discovery*, **2020**, 10, 40-53 | 24.4 | 98 |
| 83 | Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2020**, 21, 44-59 | 21.7 | 422 |
| 82 | Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. *Lancet Oncology, The*, **2020**, 21, 1283-1295 | 21.7 | 62 |
| 81 | Current and emerging biologic therapies for triple negative breast cancer. *Expert Opinion on Biological Therapy*, **2020**, 1-12 | 5.4 | 5 |
| 80 | Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer. *Frontiers in Physiology*, **2020**, 11, 583333 | 4.6 | 12 |
| 79 | Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen. *OncoImmunology*, **2020**, 9, 1809926 | 7.2 | 2 |
| 78 | Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab **2019**, 7, 274 | | 17 |
| 77 | Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. *Gynecologic Oncology*, **2019**, 154, 314-322 | 4.9 | 54 |
| 76 | Development of [F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide. *Molecular Imaging*, **2019**, 18, 1536012119852189 | 3.7 | 29 |
| 75 | Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. *Clinical Cancer Research*, **2019**, 25, 3220-3228 | 12.9 | 99 |
| 74 | Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.. *Journal of Clinical Oncology*, **2019**, 37, TPS1115-TPS1115 | 2.2 | 8 |
| 73 | Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. *JAMA Oncology*, **2019**, 5, 74-82 | 13.4 | 326 |
| 72 | Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis. *JAMA Ophthalmology*, **2019**, 137, 96-100 | 3.9 | 10 |
| 71 | The dawn of immunotherapy for breast cancer. *Clinical Advances in Hematology and Oncology*, **2019**, 17, 332-335 | 0.6 | 3 |
| 70 | Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. *Cancer*, **2018**, 124, 1904-1911 | 6.4 | 25 |
| 69 | Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. *Human Gene Therapy*, **2018**, 29, 614-625 | 4.8 | 34 |

| | | | |
|---|---|---|---|
| 68 | Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. *Human Pathology*, **2018**, 74, 135-147 | 3.7 | 28 |
| 67 | Targeting adenosine for cancer immunotherapy **2018**, 6, 57 | | 228 |
| 66 | Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. *Breast Cancer Research and Treatment*, **2018**, 167, 671-686 | 4.4 | 345 |
| 65 | Breast Cancer Immunotherapy: Facts and Hopes. *Clinical Cancer Research*, **2018**, 24, 511-520 | 12.9 | 271 |
| 64 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *New England Journal of Medicine*, **2018**, 379, 2108-2121 | 59.2 | 1871 |
| 63 | Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. *International Immunopharmacology*, **2017**, 46, 112-123 | 5.8 | 18 |
| 62 | A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. *Cancer Immunology Research*, **2017**, 5, 468-479 | 12.5 | 87 |
| 61 | Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. *European Journal of Cancer*, **2017**, 81, 116-129 | 7.5 | 314 |
| 60 | PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. *Modern Pathology*, **2017**, 30, 1551-1560 | 9.8 | 30 |
| 59 | Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC).. *Journal of Clinical Oncology*, **2017**, 35, 5585-5585 | 2.2 | 34 |
| 58 | It's TIME for a biomarker-driven approach to cancer immunotherapy **2016**, 4, 43 | | 5 |
| 57 | A Novel Approach to Journal Club Designed to Immerse Trainees in a Peer-Review Process to Critically Evaluate Oncology Manuscripts. *Medical Science Educator*, **2016**, 26, 273-274 | 0.7 | |
| 56 | The immune microenvironment of breast ductal carcinoma in situ. *Modern Pathology*, **2016**, 29, 249-58 | 9.8 | 98 |
| 55 | PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. *Human Pathology*, **2016**, 47, 52-63 | 3.7 | 214 |
| 54 | Targeting the programmed cell death-1 pathway in breast and ovarian cancer. *Current Opinion in Obstetrics and Gynecology*, **2016**, 28, 142-7 | 2.4 | 35 |
| 53 | Cancer immunotherapy trials: leading a paradigm shift in drug development **2016**, 4, 42 | | 28 |
| 52 | Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y. *American Journal of Surgical Pathology*, **2016**, 40, 1090-9 | 6.7 | 4 |
| 51 | Specific immunotherapy in ovarian cancer: a systematic review. *Immunotherapy*, **2016**, 8, 1193-204 | 3.8 | 22 |

| | | | |
|---|---|---|---|
| 50 | Antagonists of PD-1 and PD-L1 in Cancer Treatment. *Seminars in Oncology*, **2015**, 42, 587-600 | 5.5 | 206 |
| 49 | The interplay of immunotherapy and chemotherapy: harnessing potential synergies. *Cancer Immunology Research*, **2015**, 3, 436-43 | 12.5 | 416 |
| 48 | Chemotherapy--A Viable Partner for Cancer Immunotherapy?. *JAMA Oncology*, **2015**, 1, 1095-7 | 13.4 | 1 |
| 47 | Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs. *American Journal of Surgical Pathology*, **2015**, 39, 939-47 | 6.7 | 7 |
| 46 | Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer **2015**, 3, 49 | | |
| 45 | Immune targeting in breast cancer. *Oncology*, **2015**, 29, 375-85 | 1.8 | 67 |
| 44 | Emerging immunotherapies in ovarian cancer. *Discovery Medicine*, **2015**, 20, 97-109 | 2.5 | 15 |
| 43 | A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. *Cancer Immunology Research*, **2014**, 2, 949-61 | 12.5 | 51 |
| 42 | Chemoimmunotherapy: reengineering tumor immunity. *Cancer Immunology, Immunotherapy*, **2013**, 62, 203-16 | 7.4 | 162 |
| 41 | Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. *Human Pathology*, **2013**, 44, 2055-63 | 3.7 | 76 |
| 40 | A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. *Breast Cancer Research and Treatment*, **2012**, 131, 915-24 | 4.4 | 50 |
| 39 | Re-purposing cancer therapeutics for breast cancer immunotherapy. *Cancer Immunology, Immunotherapy*, **2012**, 61, 1299-305 | 7.4 | 6 |
| 38 | Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. *Expert Review of Anticancer Therapy*, **2012**, 12, 1597-611 | 3.5 | 94 |
| 37 | Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. *Clinical Cancer Research*, **2012**, 18, 3462-9 | 12.9 | 259 |
| 36 | Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 153-62 | 4.4 | 15 |
| 35 | Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. *Cancer Prevention Research*, **2011**, 4, 1993-2001 | 3.2 | 20 |
| 34 | The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE□n murine macrophages. *International Immunopharmacology*, **2010**, 10, 1220-8 | 5.8 | 67 |
| 33 | Chemoimmunotherapy. *Cancer Journal (Sudbury, Mass )*, **2010**, 16, 295-303 | 2.2 | 87 |

| | | | |
|---|---|---|---|
| 32 | Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. *Clinical Breast Cancer*, **2010**, 10, 40-5 | 3 | 15 |
| 31 | Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. *Cellular Immunology*, **2010**, 263, 79-87 | 4.4 | 100 |
| 30 | GM-CSF-secreting vaccines for solid tumors: moving forward. *Discovery Medicine*, **2010**, 10, 52-60 | 2.5 | 40 |
| 29 | Invasive Lobular Carcinoma of the Male Breast: A Rare Histology in an Uncommon Disease. *Breast Care*, **2009**, 4, 36-38 | 2.4 | 7 |
| 28 | Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. *Journal of Clinical Oncology*, **2009**, 27, 5911-8 | 2.2 | 178 |
| 27 | Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. *Journal of Clinical Oncology*, **2009**, 27, 2816-22 | 2.2 | 13 |
| 26 | Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. *Journal of Clinical Oncology*, **2009**, 27, 5660-9 | 2.2 | 184 |
| 25 | GM-CSF-secreting vaccines for solid tumors. *Current Opinion in Investigational Drugs*, **2009**, 10, 1315-24 | | 11 |
| 24 | Cancer vaccines: on the threshold of success. *Expert Opinion on Emerging Drugs*, **2008**, 13, 295-308 | 3.7 | 47 |
| 23 | Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. *Journal of Clinical Investigation*, **2008**, 118, 1700-11 | 15.9 | 70 |
| 22 | Chemotherapy and tumor immunity: an unexpected collaboration. *Frontiers in Bioscience - Landmark*, **2008**, 13, 249-57 | 2.8 | 38 |
| 21 | Jump-Starting Tumor Immunity with Breast Cancer Therapeutics **2007**, 169-187 | | |
| 20 | A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. *Clinical Cancer Research*, **2007**, 13, 3951-9 | 12.9 | 169 |
| 19 | GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. *Current Opinion in Molecular Therapeutics*, **2007**, 9, 490-7 | | 17 |
| 18 | Roadmap to a better therapeutic tumor vaccine. *International Reviews of Immunology*, **2006**, 25, 415-43 | 4.6 | 28 |
| 17 | OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. *Journal of Immunology*, **2006**, 176, 974-83 | 5.3 | 94 |
| 16 | Towards a therapeutic breast cancer vaccine: the next steps. *Expert Review of Vaccines*, **2005**, 4, 831-41 | 5.2 | 3 |
| 15 | Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. *Cancer Research*, **2005**, 65, 8059-64 | 10.1 | 152 |

| | | | |
|---|---|---|---|
| 14 | Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. *Journal of Experimental Medicine*, **2005**, 201, 1591-602 | 16.6 | 369 |
| 13 | Cancer vaccines in combination with multimodality therapy. *Cancer Treatment and Research*, **2005**, 123, 227-45 | 3.5 | 12 |
| 12 | Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. *American Journal of Therapeutics*, **2005**, 12, 243-53 | 1 | 71 |
| 11 | A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. *Human Gene Therapy*, **2004**, 15, 313-37 | 4.8 | 32 |
| 10 | Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. *Breast Disease*, **2004**, 20, 13-24 | 1.6 | 18 |
| 9 | HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. *Journal of Immunology*, **2003**, 171, 2161-9 | 5.3 | 87 |
| 8 | A new twist on autologous cancer vaccines. *Cancer Biology and Therapy*, **2003**, 2, 161-3 | 4.6 | 34 |
| 7 | Cancer Vaccines: An Old Idea Comes of Age. *Cancer Biology and Therapy*, **2003**, 2, 160-167 | 4.6 | 1 |
| 6 | New findings about endocrine therapy for breast cancer. *Breast*, **2003**, 12, 368-72 | 3.6 | 2 |
| 5 | The follow-up of breast cancer. *Seminars in Oncology*, **2003**, 30, 338-48 | 5.5 | 48 |
| 4 | Cancer vaccines: an old idea comes of age. *Cancer Biology and Therapy*, **2003**, 2, S161-8 | 4.6 | 14 |
| 3 | Toward a breast cancer vaccine: work in progress. *Oncology*, **2003**, 17, 1200-11; discussion 1214, 1217-8 | 1.8 | 8 |
| 2 | A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer. *Breast Cancer Research and Treatment*, **2002**, 76, 145-56 | 4.4 | 1 |
| 1 | To Live or Not to Live□HAT Depends on GAGE?. *Cancer Biology and Therapy*, **2002**, 1, 387-389 | 4.6 | 8 |